Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


A new class of drug in the diabetes toolbox

The DAWN and SEED trials demonstrate the potential of glucokinase activators for the treatment of type 2 diabetes, but how they fit in the overall treatment algorithm remains to be determined.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Positioning dorzagliatin in future treatment paradigms.


  1. Matschinsky, F. M. Trends Pharmacol. Sci. 34, 90–99 (2013).

    CAS  Article  Google Scholar 

  2. Grimsby, J. et al. Science 301, 370–373 (2003).

    CAS  Article  Google Scholar 

  3. Guertin, K. R. & Grimsby, J. Curr. Med. Chem. 13, 1839–1843 (2006).

    CAS  Article  Google Scholar 

  4. The Dawn Study Group. Nat. Med. (2022).

  5. The SEED Study Group. Nat. Med. (2022).

  6. De Ceuninck, F. et al. Br. J. Pharmacol. 168, 339–353 (2013).

    Article  Google Scholar 

  7. Zhu, D. et al. Lancet Diabetes Endocrinol 6, 627–636 (2018).

    CAS  Article  Google Scholar 

  8. Vella, A. et al. Sci. Transl. Med. 11, eaau3441 (2019).

    CAS  Article  Google Scholar 

  9. Klein, K. R. et al. Diabetes Care 44, 960–968 (2021).

    CAS  Article  Google Scholar 

  10. Chen, L. et al. Diabetes 70, 117–LB (2021).

    Article  Google Scholar 

  11. Miao, J. et al. Clin. Transl. Sci. 15, 548–557 (2022).

    CAS  Article  Google Scholar 

  12. American Diabetes Association Professional Practice Committee. Diabetes Care 45, S125–S143 (2022).

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to John B. Buse.

Ethics declarations

Competing interests

K.R.K. and J.B.B. have worked with vTv Therapeutics, the developers of the GKA TTP-399, as investigators and collaborators without direct financial benefit. J.B.B. has provided consultation to Novo Nordisk, with fees paid to the University of North Carolina; has grant support from Dexcom, NovaTarg, Novo Nordisk, Sanofi, Tolerion and vTv Therapeutics; is a consultant with personal compensation from Alkahest, Altimmune, Anji, AstraZeneca, Bayer, Boehringer-Ingelheim, CeQur, Cirius Therapeutics Inc., Dasman Diabetes Center (Kuwait), Eli Lilly, Fortress Biotech, GentiBio, Glycadia, Glyscend, Janssen, Mediflix, Medscape, Mellitus Health, Pendulum Therapeutics, Praetego, Stability Health, Valo and Zealand Pharma; and has received stock options from Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego and Stability Health.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Klein, K.R., Buse, J.B. A new class of drug in the diabetes toolbox. Nat Med 28, 901–902 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing